Daily Hong Kong Stock Market News Express (Thursday, February 20)

< br > < span class = "section-news" > 1. 09880.HK announced on the Hong Kong Stock Exchange that it will place 10,155,099 new H shares at a price of HK $90.00 per H share. < br > < span class = "section-news" > 2. IMAX China (01970.HK): Net profit for the full year 2024 is US $22.20 million, compared to US $27.50 million for the same period last year. < br > < span class = "section-news" > 3. Huishang Bank (03698.HK): It is expected that net profit in 2024 will be about 15.90 billion yuan, an increase of about 6% year-on-year. < br > < span class = "section-news" > 4. Tianqi Lithium (09696.HK): TLEA management has conducted asset impairment tests on overseas lithium hydroxide projects. < br > < span class = "section-news" > 5. Cathay Pacific (00293.HK): Passenger 2.352 million in January, an increase of 37% year-on-year. < br > < span class = "section-news" > 6. Le Class Logistics (02490.HK): It is expected that the net profit in 2024 will 359 million - 419 million yuan, an increase of 199% to 249% year-on-year. < br > < span class = "section-news" > 7. Yingda Real Estate (00432.HK): It is expected to generate revenue of HK $9.01 in 2024, an increase of 9.61% year-on-year, and a net loss of HK $230 million, a decrease of 50.64% year-on-year. < br > < span class = "section-news" > 8. Haohai Biotechnology (06826.HK): Revenue of 2.698 billion yuan in 2024, an increase of 1.64% year-on-year; net profit attributable to the parent 420 million yuan, an increase of 0.97% year-on-year. < br > < span class = "section-news" > 9. Goree Pharmaceutical-B (01672.HK): Small molecule oral GLP-1R agonist ASC30 The first two cohorts of the US Phase Ib multi-dose escalation study achieved positive interim results.